Overview

This trial is active, not recruiting.

Conditions chronic lymphocytic leukemia, small lymphocytic lymphoma
Treatments ibrutinib, bendamustine hydrochloride, rituximab, placebo
Phase phase 3
Targets BTK, CD20
Sponsor Janssen Research & Development, LLC
Collaborator Pharmacyclics LLC.
Start date September 2012
End date January 2019
Trial size 580 participants
Trial identifier NCT01611090, 2012-000600-15, CR100840, PCI-32765CLL3001, U1111-1135-3745

Summary

The purpose of this study is to examine the safety and efficacy of Ibrutinib administered in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification safety/efficacy study
Intervention model parallel assignment
Masking double blind (subject, caregiver, investigator)
Primary purpose treatment
Arm
(Experimental)
Ibrutinib 420 mg will be administered orally once daily on a continuous schedule. All subjects will receive background therapy with bendamustine and rituximab (BR) for a maximum of 6 cycles (a cycle is defined as 28 days, with the exception of Cycle 1, which will be 29 days to allow for rituximab dosing prior to bendamustine and study medication).
ibrutinib
Type=exact number, unit=mg, number=420 , form=capsule, route=oral use. Capsule is taken once daily continuously.
bendamustine hydrochloride
Type=exact number, unit=mg, number=70 mg/m2, route=intravenous use. Administered intravenously on Cycle 1, Days 2-3 and Cycles 2-6, Days 1-2.
rituximab
Type=exact number, unit=mg, number=375 mg/m2 and 500 mg/m2, route=intravenous use. Administered intravenously on Cycle 1, Day 1, and Cycles 2-6, Day 1, respectively.
(Placebo Comparator)
Matching placebo will be administered orally once daily on a continuous schedule. All subjects will receive background therapy with BR for a maximum of 6 cycles (a cycle is defined as 28 days, with the exception of Cycle 1, which will be 29 days to allow for rituximab dosing prior to bendamustine and study medication).
bendamustine hydrochloride
Type=exact number, unit=mg, number=70 mg/m2, route=intravenous use. Administered intravenously on Cycle 1, Days 2-3 and Cycles 2-6, Days 1-2.
rituximab
Type=exact number, unit=mg, number=375 mg/m2 and 500 mg/m2, route=intravenous use. Administered intravenously on Cycle 1, Day 1, and Cycles 2-6, Day 1, respectively.
placebo
Form=capsule, route=oral use. Capsule is taken once daily continuously.

Primary Outcomes

Measure
Progression-free survival
time frame: Up to 5 years after the last patient is randomized

Secondary Outcomes

Measure
Number of participants with adverse events
time frame: Up to 30 days following the last dose of study drug
Overall response rate
time frame: At disease progression, up to 5 years after the last patient is randomized
Overall survival
time frame: Up to 5 years after the last patient is randomized
Rate of minimal residual disease (MRD)-negative remissions
time frame: At disease progression, up to 5 years after the last patient is randomized
Number of participants with improvement in hematologic values
time frame: At disease progression, up to 5 years after the last patient is randomized
Number of participants with improvement in disease-related symptoms
time frame: At disease progression, up to 5 years after the last patient is randomized
Number of participants with improvement in patient-reported outcome scores
time frame: At disease progression, up to 5 years after the last patient is randomized
Plasma concentrations of ibrutinib
time frame: Up to Day 2, Cycle 6
Plasma concentrations of bendamustine
time frame: Up to Day 2, Cycle 6
Plasma concentrations of rituximab
time frame: Up to Day 1, Cycle 12
Number of participants with biomarkers related to B-cell receptors
time frame: End-of-treatment visit (up to Day 450)

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - Diagnosis of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that meets protocol-defined criteria - Active disease meeting at least 1 of the International Workshop on Chronic Lymphocytic Leukemia 2008 criteria for requiring treatment - Measurable nodal disease by computed tomography - Relapsed or refractory CLL or SLL following at least 1 prior line of systemic therapy consisting of at least 2 cycles of a chemotherapy-containing regimen - Eastern Cooperative Oncology Group Performance Status score of 0 or 1 - Hematology and biochemical values within protocol-defined limits - Agrees to protocol-defined use of effective contraception - Women of childbearing potential must have negative blood or urine pregnancy test at screening Exclusion Criteria: - Recent therapeutic interventions within 3 (chemotherapy/radiotherapy) to 10 weeks (immunotherapy) - Prior treatment with ibrutinib or other Bruton's tyrosine kinase inhibitors or prior randomization in any other clinical study evaluating ibrutinib - The presence of deletion of the short arm of chromosome 17 - Patients previously treated with a bendamustine-containing regimen who did not achieve a response or who relapsed and required treatment within 24 months of treatment with that regimen - Patients for whom the goal of therapy is tumor debulking prior to stem cell transplant - Received a hematopoietic stem cell transplant - Known central nervous system leukemia/lymphoma or Richter's transformation - Patients with uncontrolled autoimmune hemolytic anemia or autoimmune thrombocytopenia - Chronic use of corticosteroids - History of prior malignancy, except: malignancy treated with curative intent and with no known active disease present for >=3 years before randomization; adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease; adequately treated cervical carcinoma in situ without evidence of disease - History of stroke or intracranial hemorrhage within 6 months prior to randomization; or clinically significant cardiovascular disease - Requires anticoagulation with warfarin or equivalent vitamin K antagonists or treatment with strong CYP3A4/5 inhibitors - Known history of human immunodeficiency virus or hepatitis C, or active infection with hepatitis B or C - Any uncontrolled active systemic infection or any life-threatening illness, medical condition, or organ system dysfunction which, in the investigator's opinion, could compromise the patient's safety, interfere with the absorption or metabolism of ibrutinib capsules, or put the study outcomes at undue risk - A woman who is pregnant or breast feeding, or a man who plans to father a child while enrolled in this study or within 3 months after the last dose of study drug

Additional Information

Official title Randomized, Double-blind, Placebo-controlled Phase 3 Study of Ibrutinib, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Combination With Bendamustine and Rituximab (BR) in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Description This is a randomized (patients will be assigned by chance to study treatments), double-blind (patients and study personnel will not know the identity of study treatments), placebo (an inactive substance that is compared with a drug to test whether the drug has a real effect in a clinical trial)-controlled study to determine the benefits and risks of combining ibrutinib with bendamustine and rituximab (BR) in patients with relapsed or refractory CLL/SLL following at least 1 line of prior systemic therapy. Approximately 580 patients will be randomized in a 1:1 ratio to either treatment arm A (placebo) or treatment arm B (ibrutinib 420 mg). Study medication will be administered orally once daily on a continuous schedule. All patients will receive BR as the background therapy plus either ibrutinib or placebo for a maximum of 6 cycles, after which treatment with ibrutinib or placebo will continue until disease progression or unacceptable toxicity. A treatment cycle will be defined as 28 days. The study will include a screening phase, a treatment phase, and a follow-up phase. Study end is defined as when either 80% of the patients have died or 5 years after the last patient is randomized into the study, whichever occurs first. Patients in treatment arm A (placebo) who complete the treatment phase, with disease progression or (after interim analysis) meet International Workshop on Chronic Lymphocytic Leukemia (IWCLL) criteria for treatment, may crossover to ibrutinib treatment (as in treatment arm B), at the investigators discretion. This open-label, next-line treatment with ibrutinib will continue until disease progression, unacceptable toxicity, withdrawal from study, or until the study end, whichever occurs earlier. One interim analysis is planned for the study. Efficacy evaluations will include computed tomography scans, laboratory testing, focused physical examinations, bone marrow biopsy and aspirate, and assessment of patient-reported outcomes. In both treatment arms, samples for the development of a population-based pharmacokinetic (PK; study of what the body does to a drug) approach will be collected. Safety will be assessed throughout the study.
Trial information was received from ClinicalTrials.gov and was last updated in November 2016.
Information provided to ClinicalTrials.gov by Janssen Research & Development, LLC.